文献类型：期刊文献

英文题名：Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials

作者：Chen, Ting[1,2];Huang, Junyue[2];Dong, Hui[2];Xu, Lili[1,2];Chen, Caihe[1,2];Tang, Yu[3];Huang, Wenhui[2]

第一作者：Chen, Ting;陈涛;陈腾

通信作者：Huang, WH[1];Tang, Y[2]

机构：[1]Gansu Univ Tradit Chinese Med, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Dept Nephrol, Lanzhou, Peoples R China;[3]Gansu Prov Hosp, Clin Lab, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Nephrol, Lanzhou, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Clin Lab, Lanzhou, Peoples R China.

年份：2022

卷号：9

外文期刊名：FRONTIERS IN NUTRITION

收录：;Scopus(收录号：2-s2.0-85143268840);WOS:【SCI-EXPANDED(收录号:WOS:000892609300001)】；

基金：This work was supported by the Natural Science Foundation of Gansu Province (Grant No. 20JR10RA398).

语种：英文

外文关键词：chronic kidney disease; non-dialysis; anemia; roxadustat; meta-analysis; efficacy; hemoglobin; clinical trials

摘要：ObjectiveTo evaluate the efficacy and safety of roxadustat in the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.Materials and methodsFor this systematic review and meta-analysis, we searched for randomized controlled trials (RCTs) of anemia in NDD-CKD patients to assess the efficacy and safety of roxadustat. The primary efficacy endpoint was the proportion of patients who achieved a hemoglobin (Hb) response. Secondary efficacy endpoints were hepcidin, serum iron, serum ferritin (SF), total iron-binding capacity (TIBC), transferrin saturation (TAST), and low-density lipoprotein (LDL). In addition, adverse events (AEs) were compared. Meta-analyses were performed using Revman 5.4 software. The quality of the evidence was assessed using the Cochrane risk of bias tool. This study was conducted under a pre-established protocol registered with PROSPERO (registration number: CRD42021252331).ResultsSeven studies enrolled 4,764 patients, of whom 2,730 received roxadustat and 2,034 received placebo. The results of this meta-analysis showed that roxadustat increased Hb levels [weighted mean difference (WMD) = 1.43, 95% CI: 1.17 to 1.68, P < 0.001, I-2 = 95%], and Hb response [relative ratio (RR) = 8.12, 95% CI: 5.80 to 11.37, P < 0.001, I-2 = 61%]. In addition, roxadustat significantly increased transferrin TAST. During the treatment period in patients with anemia, the AEs of roxadustat compared with placebo was not statistically significant.ConclusionRoxadustat can improve anemia in NDD-CKD patients by increasing Hb levels and regulating iron metabolism, but does not increase the incidence of AEs.Systematic review registration[], identifier [CRD42021252331].